Efficacy and safety of vibegron in overactive bladder patients with inadequate effect of antimuscarinics and mirabegron treatment

Imamura Ryoichi0 个研究点目标入组 30 人开始时间: 2023年9月29日最近更新: 2023年10月17日

试验速览

暂无简介。

•Patients with OAB defined as an OAB symptom score (OABSS) for Q3 (urgency) of two or more and a total score of three or more and patients who have been taking a treatment other than Vivegron for overactive bladder for at least 12 weeks.

•(1) Patients who have already been diagnosed with overactive bladder and have previously taken Vivegron.
•(2) Patients who are unable to complete the questionnaire on their own.
•(3) Patients with severe hepatic dysfunction and renal dysfunction.
•(4) Patients who wish to become pregnant or have a baby in the future
•(5) Patients who are allergic to be-ta 3 agonists.
•(6) Pregnant women, women who may become pregnant, and nursing mothers.
•(7) Patients with serious cardiac disease.
•(8) Patients with urinary retention.
•(9) Patients who are currently participating in a clinical study involving an intervention or who have participated in another clinical study involving an intervention within 4 months (If the patient is participating in an observational study, check whether the patient violates the exclusion or discontinuation criteria of the observational study).
•(10) Patients deemed inappropriate as research subjects by the principal investigator.
•those who are allergic to mirabegron and vibegron, are unable to complete the questionnaire on their own, wish to become pregnant or have a baby in the future, are participating in clinical studies involving interventions and those who are considered to be inappropriate by the physician, pregnant women, women who may be pregnant, and nursing mothers and patients with severe hepatic dysfunction and renal dysfunction, serious cardiac disease and urinary retention.

发起方

Imamura Ryoichi